Retatrutide in 2026: The Triple Agonist Explained

Retatrutide is Eli Lilly's investigational triple agonist — a single molecule that binds glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is not FDA-approved. It is currently in Phase 3 across the TRIUMPH program (obesity) and TRANSCEND-T2D (type 2 diabetes). This post walks through what the published data actually shows, how Retatrutide differs mechanistically from Semaglutide and Tirzepatide, and why "investigational" is a load-bearing word.

The mechanism, in one paragraph

Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide adds GIP agonism, which appears to contribute to both greater weight loss and improved glycemic control. Retatrutide adds glucagon receptor agonism on top of both, which is counterintuitive — glucagon raises blood glucose — but at the balanced doses used clinically, the net effect is increased energy expenditure and hepatic fat mobilisation without the hyperglycemia you'd expect from glucagon monotherapy.

What the Phase 3 data actually shows

The TRIUMPH-1 trial of adults with obesity (no type 2 diabetes) reported mean weight loss of up to 28.7% at 48 weeks on the 12 mg weekly dose. That figure is from Lilly's publicly announced topline readout. For context:

• Semaglutide 2.4 mg weekly (STEP-1): ~14.9% weight loss at 68 weeks
• Tirzepatide 15 mg weekly (SURMOUNT-1): ~22.5% weight loss at 72 weeks
• Retatrutide 12 mg weekly (TRIUMPH-1 topline): ~28.7% at 48 weeks

These are different trials with different populations and different time horizons, so direct comparison has limits. The rough ordering — GLP-1 < GIP/GLP-1 dual < GIP/GLP-1/glucagon triple — is consistent with the mechanistic theory.

Published dosing

The Phase 3 titration schedule holds four weeks at each dose before escalating:

• Weeks 1–4: 2 mg weekly
• Weeks 5–8: 4 mg weekly
• Weeks 9–12: 6 mg weekly
• Weeks 13–16: 9 mg weekly
• Weeks 17+: 12 mg weekly (maintenance in the trial)

The slow titration matters. The most common adverse events in the published data are gastrointestinal — nausea, diarrhea, vomiting — and they concentrate at dose escalations. Four-week holds exist for a reason.

See the Retatrutide compound page for the full clinical dose range, citations, and reconstitution defaults.

Regulatory status in 2026

Retatrutide is investigational. That means:

• No FDA-approved indication.
• Not legally available outside Lilly's clinical trials in the United States.
• Research-grade material circulating in the peptide aftermarket is not the same molecule in a meaningful regulatory sense — there is no approved label, no QC chain of custody, and no Phase 3 safety surveillance applied to it.

Peply does not sell Retatrutide and has no opinion on where or whether anyone should obtain it. What we can say factually: the evidence base for Retatrutide is Phase 3 trial data, which is substantially stronger than the "limited human data" label most peptides carry, but substantially weaker than an approved product's post-market surveillance.

How to think about this if you're tracking the space

A few concrete things to watch:

1. TRIUMPH-2 and TRIUMPH-3 readouts. Obesity with type 2 diabetes, and obesity with knee osteoarthritis, respectively. These should report across 2026–2027.
2. TRANSCEND-T2D-1 readout. Head-to-head with Dulaglutide in T2D. The comparison matters for payer positioning post-approval.
3. The FDA submission timeline. Lilly has guided toward filing in 2026. Approval lags filing by roughly a year under priority review.
4. Manufacturing supply. Tirzepatide supply constraints shaped its real-world availability for two years. Retatrutide will start from the same base.

For the math side of things

If you're reading Retatrutide protocols in the published literature and want to work out what a specific weekly dose looks like in draw volume and syringe units, the reconstitution calculator handles it. Select Retatrutide in the compound picker, enter the vial and diluent volumes from your source, and it will return concentration, draw volume, and units for the standard insulin syringes.

Disclaimer

Retatrutide is investigational. This post summarises published clinical data and reported topline trial results. It is not medical advice, not a vendor recommendation, and not an endorsement of any sourcing path. Consult a licensed healthcare provider before making any dosing or treatment decisions.

See the compound page for all citations with lastReviewedAt dates, or the regulatory tracker for current FDA category status across the peptide space.